EXACT SCIENCES CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.45 USD | +0.44% |
|
-8.81% | -38.56% |
| 05-24 | Sector Update: Health Care Stocks Advance Pre-Bell Friday | MT |
| 05-24 | Exact Sciences to Present New Data at Oncology Annual Meeting Confirming Prognostic Value of Breast Cancer Test | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- The company's enterprise value to sales, at 3.52 times its current sales, is high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -38.56% | 8.39B | A- | ||
| +0.18% | 3.32B | C | ||
| +9.29% | 2.48B | D+ | ||
| -18.21% | 2.06B | - | B- | |
| -24.57% | 1.59B | C+ | ||
| +32.37% | 1.15B | B- | ||
| -7.64% | 704M | C+ | ||
| +8.42% | 678M | C- | ||
| -29.59% | 508M | C- | ||
| -6.56% | 273M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- EXAS Stock
- Ratings Exact Sciences Corporation
